Exabis Library
Welcome to the e-CCO Library!
DOP033: Trends in epidemiology of Inflammatory Bowel Disease among Jewish Israeli adolescents: A population based study
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP034: Assessment of direct healthcare cost drivers of Crohn’s disease in a Dutch population-based cohort study shows a major shift
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP034: Assessment of direct healthcare cost drivers of Crohn's Disease in a Dutch population-based cohort study shows a major shift
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn’s disease: results from a real-life population-based cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn’s disease: results from a real-life population-based cohort
2016
ECCO'16 DOP
1
DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn's disease patients treated with adalimumab for prevention of postoperative recurrence
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn’s Disease patients treated with adalimumab for prevention of postoperative recurrence
2017
ECCO'17 Barcelona
1
DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD
2017
ECCO'17 Barcelona
1
DOP035: Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP035: Longterm outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents
2016
ECCO'16 DOP
1
DOP036: Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation
2017
ECCO'17 Barcelona
1
DOP036: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study (ICC case series)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP036: Ustekinumab for Crohn's Disease: A nationwide real-life observational cohort study (ICC Case Series)
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP037: A model for prediction of early surgery and complications in paediatric Crohn's disease: results of the prospective GROWTH CD study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP037: A model for prediction of early surgery and complications in paediatric Crohn’s Disease; Results of the prospective GROWTH CD study
2017
ECCO'17 Barcelona
1